TLR9 and neoplasm: Another study proved, in the animal models, that tumor therapeutic vaccine compound of TLR9 agonists (CpG ODN) and irradiated tumor cell tracking of two other CpG ODNs injections lead to a long-term antitumor immune response against aggressive tumors.